In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it may be effective in preserving the vision of people with wet age-related macular degeneration (AMD). AMD is a leading cause of vision loss in the U.S., affecting an estimated 1.6 million Americans.
The disease is marked by growth of abnormal blood vessels that leak fluid into the central portion of the retina called the macula, which we use for reading, driving and recognizing faces.
The study published on May 16 in The Lancet, reports an exciting new approach in which a virus, similar to the common cold, but altered in the lab so that it is unable to cause disease, is used as a carrier for a gene and is injected into the eye. The virus penetrates retinal cells and deposits a gene, which turns the cells into factories for productions of a therapeutic protein, called sFLT01.
The abnormal blood vessels that cause wet AMD grow because patients have increased production of vascular endothelial growth factor (VEGF) in their retinas. Current treatments require injections of proteins directly into the eye that bind and inactivate VEGF, reducing fluid in the macula and improving vision. However, the therapeutic proteins exit the eye over the course of a month, so patients with wet AMD usually need to return to the clinic for more injections every six to eight weeks in order to stave off vision loss. Eye specialists say the burden and discomfort of the regimen is responsible for many patients not getting injections as frequently as they need, causing vision loss.
Because viruses naturally penetrate cells and leave behind genetic material, the investigators designed their virus to target retinal cells and provide them with a gene that produces sFLT01. Thus, retinal cells become factories that produce the therapeutic protein — potentially eliminating the need to repeatedly inject it.
“This preliminary study is a small but promising step towards a new approach that will not only reduce doctor visits and the anxiety and discomfort associated with repeated injections in the eye, but may improve long-term outcomes because prolonged suppression of VEGF is needed to preserve vision, and that is difficult to achieve with repeated injections because life often gets in the way,” says Peter Campochiaro, M.D., the George S. and Dolores D. Eccles Professor of Ophthalmology at the Johns Hopkins University School of Medicine.
The phase 1 clinical trial involved 19 men and women, 50 years old or older with advanced wet AMD.
Participants were divided into five different groups that received increasing doses from 2X10^8 to 2X10^10 viral particles containing the therapeutic gene in 0.05 mL of fluid. Each group was examined by investigators for signs of adverse reactions for at least 4 weeks before administering a higher dose to the next group.
After the virus deposited the gene, the cells began secreting sFLT01 which bound to VEGF and prevented it from stimulating leakage and growth of abnormal blood vessels. The goal is for the retinal cells infected by the virus to produce enough sFLT01 to permanently stop the progression of AMD.
After monitoring the first three groups and finding no dose-limiting toxicity, the researchers administered the maximum dose to a group of ten participants and observed no serious side effects. “Even at the highest dose, the treatment was quite safe. We found there were almost no adverse reactions in our patients,” Campochiaro says.
For safety and ethical reasons, the study group was composed of people for whom standard approved treatments were highly unlikely to regain vision, meaning in part that only 11 of the 19 had the potential for fluid reduction. Of those eleven patients, four showed dramatic improvements. The amount of fluid in their eyes dropped from severe to almost nothing, just like what is observed with optimal standard treatment, Campochiaro says. In addition, two other participants showed a partial reduction in the amount of fluid in their eyes.
Five participants showed no reduction in fluid levels. Surprisingly, the researchers say, they found that all of the patients who did not show improvement had pre-existing antibodies to the AAV2 virus.
From that result, the researchers conclude that even if further studies affirm the safety and value of their gene therapy, it may have limitations for broad use. That’s because an estimated sixty percent of the U.S. population has been infection with adeno-associated virus, the family of viruses that AAV2 belongs to, and have built an immunity to it. The researchers believe that in these patients, the immune system destroyed the virus before it could insert the therapeutic gene. Campochiaro explains, “The numbers are small and simply show a correlation, so we don’t know if serum antibodies are definitely an impediment, but more work is needed to determine this.”
The Latest on: Wet age-related macular degeneration
- Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration on December 17, 2018 at 6:00 am
SAN CARLOS, Calif., Dec. 17, 2018 /PRNewswire/ -- Alkahest Inc., a clinical-stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced to... […]
- Age-Related Macular Degeneration Market Is Expected to Expand at an Impressive Rate by 2025 on December 11, 2018 at 10:47 pm
Lack of trained ophthalmologists, high cost of drugs for wet AMD, and associated high risk are some major challenges before the AMD market. The age-related macular degeneration market can be broadly c... […]
- Wet Age-Related Macular Degeneration: The European Market and Competitive Landscape (2018-2023) - ResearchAndMarkets.com on December 11, 2018 at 2:37 am
The "Wet Age-Related Macular Degeneration: The European Market and Competitive Landscape (2018-2023)" report has been added to ResearchAndMarkets.com's offering. Wet Age-Related Macular Degeneration: ... […]
- Opthea Provides Update on Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum on October 29, 2018 at 2:42 am
The purpose of the trial was to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis ® in p... […]
- New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD) on October 27, 2018 at 10:32 am
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in t... […]
- New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD) on October 27, 2018 at 7:28 am
SOUTH SAN FRANCISCO, Calif.--(Business Wire)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase II STAIRWAY study which explored the ... […]
- New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD) on October 27, 2018 at 7:20 am
“Because current anti-VEGF monotherapies for wet AMD are burdensome, requiring frequent clinic visits for eye injections, some people are under-treated and experience subsequent declining vision over ... […]
- Global Wet Age-Related Macular Degeneration Market and Competitive Landscape to 2023 on October 26, 2018 at 10:44 am
The "Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Global Wet Age-Related Macular Degeneration Market ... […]
- Global Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2018 - ResearchAndMarkets.com on October 26, 2018 at 6:32 am
DUBLIN--(BUSINESS WIRE)--The "Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Global Wet Age-Related Ma... […]
- Age-related macular degeneration: What you should know on July 30, 2018 at 12:00 am
Age-related macular degeneration (AMD) is the leading cause of vision loss ... There are two types of AMD: dry and wet. Dry AMD is characterized by the thinning and aging of the macular tissue. About ... […]
via Google News and Bing News